- Triweekly carboplatin is associated with similar effectiveness and better safety than high-dose cisplatin in patients receiving chemoradiation for stage I/II human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC).
Why this matters
- Triweekly carboplatin may represent a safer treatment option for patients with early-stage disease.
- In stage I/II disease, high-dose cisplatin and triweekly carboplatin were associated with similar locoregional recurrence (LR), distant metastasis (DM), overall recurrence (OR), OS, and cause-specific survival (CSS; all P>.05).
- In stage III disease, high-dose cisplatin was associated with lower rates of LR (9% vs 21%; HR, 0.22; P=.03), DM (7% vs 28%; HR, 0.15; P=.006), and OR (14% vs 40%; HR, 0.20; P=.002).
- Cisplatin was superior to carboplatin for OS (89% vs 78%; HR, 0.34; P=.04) and CSS (95% vs 80%; HR, 0.18; P=.02).
- Carboplatin was associated with lower rates of grade 3 leukopenia (11.0% vs 24.8%; P<.001 weight loss from baseline vs p gastrostomy-tube placement and emergency department visit within days of treatment>
- 421 with HPV-associated OPSCC: 230 treated with high-dose cisplatin and 191 with triweekly carboplatin, were included.
- Funding: Kaiser Permanente Regional Research Committee.
- Retrospective study.